ResearcherJesse Brown VA Medical CenterActive in the last 2 years
Mario A. Shields
Matched on ORCID iD 0000-0002-3562-9875; OpenAlex author ID A5020129454; NIH RePORTER profile ID 15813051. Sources: OpenAlex.
Their work
- Papers
- 10 (first author 2, last author 0)
- Trials
- 0
- Grants
- 1
- Labs led
- 2
- Collaborators
- 20
2011: 2 papers · 2012: 3 papers · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: none · 2026: 1 paper, 1 grant
Papers 10
- DNA methylation-based classification uncovers acinar and ductal origins for KPC-derived PDAC cell lines. Co-author DOI 10.1016/j.canlet.2026.218666↗
- Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-3574↗
- Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells. Co-author DOI 10.1158/1535-7163.mct-23-0833↗
- Gα13 loss in Kras/Tp53 mouse model of pancreatic tumorigenesis promotes tumors susceptible to rapamycin. Co-author DOI 10.1016/j.celrep.2022.110441↗
- Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. First author DOI 10.3390/cancers13030440↗
- Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. First author DOI 10.1016/j.jss.2011.09.020↗
- Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. Co-author DOI 10.1042/bj20111240↗
- Interplay between β1-integrin and Rho signaling regulates differential scattering and motility of pancreatic cancer cells by snail and Slug proteins. Co-author DOI 10.1074/jbc.m111.308940↗
- Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. Co-author DOI 10.1074/jbc.m110.195628↗
- Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Co-author DOI 10.1158/0008-5472.can-10-1855↗
Grants 1
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hidayatullah G. Munshi · 9 shared papers, 2011–2024 · strength 0.95
- Paper Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer. DOI 10.1158/0008-5472.can-23-3574↗
- Paper Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells. DOI 10.1158/1535-7163.mct-23-0833↗
- Paper Gα13 loss in Kras/Tp53 mouse model of pancreatic tumorigenesis promotes tumors susceptible to rapamycin. DOI 10.1016/j.celrep.2022.110441↗
- Thao D. Pham · 4 shared papers, 2021–2024 · strength 0.76
- Paper Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer. DOI 10.1158/0008-5472.can-23-3574↗
- Paper Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells. DOI 10.1158/1535-7163.mct-23-0833↗
- Paper Gα13 loss in Kras/Tp53 mouse model of pancreatic tumorigenesis promotes tumors susceptible to rapamycin. DOI 10.1016/j.celrep.2022.110441↗
- David J. Bentrem · 6 shared papers, 2011–2024 · strength 0.49
- Paper Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells. DOI 10.1158/1535-7163.mct-23-0833↗
- Paper Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. DOI 10.3390/cancers13030440↗
- Paper Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. DOI 10.1016/j.jss.2011.09.020↗
- Jeffrey H. Becker · 2 shared papers, 2024 · strength 0.45
- Paper Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer. DOI 10.1158/0008-5472.can-23-3574↗
- Paper Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells. DOI 10.1158/1535-7163.mct-23-0833↗
- Daniel R. Principe · 2 shared papers, 2021–2024 · strength 0.36
- Rémy Nicolle · 1 shared paper, 2026 · strength 0.24
- Sofia Ferreira · 1 shared paper, 2026 · strength 0.24
- Ilianna Zoi · 1 shared paper, 2026 · strength 0.24
- Marc P. Stemmler · 1 shared paper, 2026 · strength 0.24
- Malak Haidar · 1 shared paper, 2026 · strength 0.24
- Ben Z. Stanger · 1 shared paper, 2026 · strength 0.24
- Janel L. Kopp · 1 shared paper, 2026 · strength 0.24
- Laura D Attardi · 1 shared paper, 2026 · strength 0.24
- Patrick Jacquemin · 1 shared paper, 2026 · strength 0.24
- Dhavan Shah · 1 shared paper, 2024 · strength 0.22
- Surabhi Y. Dangi-Garimella · 5 shared papers, 2011–2012 · strength 0.19
- Paper Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. DOI 10.1042/bj20111240↗
- Paper Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. DOI 10.1016/j.jss.2011.09.020↗
- Paper Interplay between β1-integrin and Rho signaling regulates differential scattering and motility of pancreatic cancer cel… DOI 10.1074/jbc.m111.308940↗
- Seth B. Krantz · 4 shared papers, 2011–2012 · strength 0.14
- Paper Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. DOI 10.1016/j.jss.2011.09.020↗
- Paper Interplay between β1-integrin and Rho signaling regulates differential scattering and motility of pancreatic cancer cel… DOI 10.1074/jbc.m111.308940↗
- Paper Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metal… DOI 10.1074/jbc.m110.195628↗
- Patrick W. Underwood · 1 shared paper, 2021 · strength 0.13
- Jose Gilberto Trevino · 1 shared paper, 2021 · strength 0.13
- Paul J. Grippo · 1 shared paper, 2011 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.